This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Paclitaxel poliglumex
- DrugBank Accession Number
- DB13809
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Synonyms
- Paclitaxel poliglumex
- External IDs
- CT-2103
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex. Ambroxol The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Ambroxol. Amsacrine The risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel poliglumex. Anastrozole The risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel poliglumex. Arsenic trioxide The risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel poliglumex. - Food Interactions
- Not Available
Categories
- ATC Codes
- L01CD03 — Paclitaxel poliglumex
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- TQ64FZ98ZN
- CAS number
- 263351-82-2
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at June 23, 2017 20:49 / Updated at February 21, 2021 18:54